260 Mg Paclitaxel Injection IP

Name: 260 Mg Paclitaxel Injection IP
Brand: NEETCO BIOPHARMA
Price: 800 INR
Availability: InStock

Price 800 INR/ Vial

Get a Price/Quote

MOQ : 1 Vial

260 Mg Paclitaxel Injection IP Specification

Salt Composition
Paclitaxel 260 mg

Dosage Form
Injection

Indication
Anticancer, ovarian cancer, breast cancer, non-small cell lung cancer

Enzyme Types
Non-enzymatic cytotoxic agent

Feature
Preservative-free, ready-to-use, single vial

Ingredients
Paclitaxel, Cremophor EL, Ethanol

Application
Intravenous infusion

Physical Color/Texture
Clear to pale yellow solution

Fermentation Smell
Odorless

Enzymatic Activity
Not applicable (cytotoxic chemotherapy agent)

Storage Instructions
Store below 25°C, protect from light

Shelf Life
24 months

Compatibility
Compatible with normal saline and dextrose infusion solutions

Warning
Cytotoxic, handle with care

Visual Inspection
No visible particles

Container Type
Glass vial, sealed with rubber stopper

Route of Administration
Intravenous use only

Adverse Effects
Neutropenia, alopecia, neuropathy, myalgia

USP Compliance
Manufactured under USP standards

Contraindications
Hypersensitivity to paclitaxel or formulation components

Prescription
Prescription only medicine

Pack Size
5 ml and 43.4 mg/ml concentration

About 260 Mg Paclitaxel Injection IP

Elevate oncology care with the elite 260 Mg Paclitaxel Injection IP, a marvelously formulated, preservative-free antineoplastic agent crafted under strict USP standards. Each wondrous glass vial contains a clear to pale yellow solution (43.4 mg/ml, 5 ml pack), ready for instant checkout by distributors, suppliers, and traders across India. Specifically manufactured for intravenous use, this unbeatable, single-dose medicine supports the treatment of ovarian, breast, and non-small cell lung cancers. Prescribed by professionals only, it ensures no visible particles and offers compatibility with both saline and dextrose infusions. Cytotoxic warning applies; careful handling is essential.

Dedicated Intravenous Application & Oncologic Uses

260 Mg Paclitaxel Injection IP is marvelously designed for intravenous infusion, ensuring rapid, direct delivery to the bloodstream. It is principally used as an antineoplastic agent in ovarian, breast, and non-small cell lung cancers. This preservative-free formulation is suitable for hospital and clinic settings, benefiting patients needing elite chemotherapy regimens. The clear-to-pale yellow solution is compatible with both saline and dextrose, supporting versatile clinical applications in oncology.

Sample Availability, Delivery Logistics & Supply Management

Sample vials of 260 Mg Paclitaxel Injection IP are readily available for healthcare institutions seeking quality verification. Goods transport is organized efficiently, ensuring timely order completion even for bulk purchases. Our robust supply ability supports continuous demand in both local and exporting markets. Freight arrangements are handled with utmost care so products reach safely and securely, making the entire procurement process seamless for authorized buyers.

FAQ's of 260 Mg Paclitaxel Injection IP:

Q: How should 260 Mg Paclitaxel Injection IP be administered?

A: This injection is intended exclusively for intravenous infusion, administered by a healthcare professional in a clinical or hospital setting. Dosage timing and volume are determined by the patient's specific condition and physician's instructions.

Q: What are the primary indications for using Paclitaxel 260 mg Injection?

A: It is primarily indicated for the treatment of various cancers, including ovarian cancer, breast cancer, and non-small cell lung cancer. Your oncologist will evaluate its suitability based on your diagnosis.

Q: When can I expect delivery after placing an order for this injection?

A: We ensure that freight and goods transport are coordinated promptly following order completion, with delivery timelines dependent on your location and order size. Most shipments are dispatched within standard pharmaceutical delivery timeframes.

Q: Where is the 260 Mg Paclitaxel Injection IP manufactured and supplied from?

A: This product is distributed, exported, and supplied from licensed pharmaceutical distributors and traders based in India, who ensure compliance with all USP quality standards.

Q: What process should be followed to handle this medication safely?

A: As a cytotoxic agent, it must be handled by trained professionals wearing appropriate protective equipment. Follow hospital protocol for preparation, administration, and disposal to safeguard both patients and staff.

Q: How can healthcare centers request samples of this injection?

A: Healthcare institutions can contact authorized distributors or suppliers to request sample vials for evaluation purposes before finalizing procurement contracts.

Tell us about your requirement